Valerio Therapeutics

What Valerio Therapeutics does

Valerio Therapeutics is a clinical-stage biotechnology company listed on Euronext Growth Paris (ticker: ALVIO) that has repositioned itself around preclinical research following the 2025 discontinuation of all clinical activities, including the VIO-01 trial. The company operates two proprietary technology platforms: the V-Body platform, based on ultra-small single-domain antibodies (~15 kDa) derived from fully synthetic human VH and humanized VHH libraries, and a Fully Integrated Chemistry platform providing advanced linker and payload capabilities for drug conjugate development. Together these platforms are designed to enable precision-guided targeted delivery of therapeutics with deep tissue penetration across modalities including antibody-drug conjugates (ADCs), bispecific T-cell engagers (BiTEs), CAR-T sdAbs, and V-Body-oligonucleotide conjugates.

The company's therapeutic focus spans oncology (solid tumors, which account for 90% of new cancer cases and over 10 million annual deaths), immuno-inflammatory and autoimmune diseases (affecting approximately 800 million people globally), and rare metabolic diseases (impacting more than 300 million patients with over 90% lacking approved treatments). In May 2026, Valerio launched InVimmune, a wholly-owned subsidiary extending its platform into in vivo cell therapy across oncology, fibrosis, and autoimmune indications. The scientific advisory board includes Nobel laureate Frederick Ramsdell and prominent immunology experts, and the company is anchored within the Paris-Saclay Cancer Cluster following its March 2026 relocation to The Hive by Kadans in Villejuif, France.

Valerio generates revenue primarily from royalties under license agreements and partnership agreements, with FY2025 revenue of €2.6 million (compared to €1.8 million in FY2024). The company is pre-commercial, with no product sales, and its go-to-market motion is to advance candidates to key development milestones and then monetize via out-licensing, co-development, and R&D collaborations with pharmaceutical, biotechnology, and academic partners. A binding term-sheet signed in May 2026 with a stealth-mode biotech provides potential aggregate milestone payments of up to USD 200 million plus tiered royalties. Major shareholders include Artal International SCA (45%), Financière de la Montagne (18.51%), and Esperanza 2019 (8.59%), following a €6.36 million capital increase completed in October 2025.

Name

Valerio Therapeutics

Legal name

Valerio Therapeutics

Website

https://valeriotx.com

Company type

Public

Founded year

2005

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Biotechnology Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics) (HLAAAIAH)

akta.pro secondary industry

mRNA Therapeutics (vaccines, protein replacement, immuno-oncology) (HLAAADAA)

Keywords

• Single-domain antibodies
• Antibody-drug conjugates
• Precision oncology therapeutics
• Targeted drug delivery
• Biotechnology platforms

Headquarters

HQ city

Lexington

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Infrastructure

Revenue model

1. Partnership and Licensing Revenue: Revenue primarily derived from royalties received under license agreements and partnership agreements. Revenue for 2025 was €2.6 million compared to €1.8 million in 2024.
2. Milestone Payments: Potential aggregate milestone payments up to USD 200 million from collaboration and exclusive license agreement, subject to execution of definitive agreement and achievement of specified events.
3. Research Tax Credit (Crédit d'Impôt Recherche): Expected receipt of €954 thousand under French Research Tax Credit program supporting preclinical R&D activities.

Go-to-market motion3 records

Distribution channels1 record

Marketing channels4 records

Core offering

Valerio Therapeutics is a clinical-stage biotechnology company developing precision-guided therapeutics through two proprietary platforms: the V-Body platform (ultra-small ~15 kDa single-domain antibodies from fully synthetic human VH and humanized VHH libraries) and a Fully Integrated Chemistry platform (advanced linker and payload technologies). The company advances therapeutic candidates through preclinical R&D in oncology, rare metabolic diseases, and immuno-inflammatory/autoimmune diseases, then out-licenses or co-develops them with pharmaceutical and biotechnology partners for clinical development and commercialization.

Product overview

Valerio Therapeutics is a clinical-stage biotechnology company pioneering next-generation precision-guided therapeutics. The company operates two proprietary technology platforms: the V-Body platform (based on ultra-small single-domain antibodies of ~15 kDa) and the Fully Integrated Chemistry platform (advanced linker and payload technology). These platforms combine to enable precise targeting and delivery of therapeutic molecules to deep tissues. The company also launched InVimmune, a subsidiary focused on in vivo cell therapy. Therapeutic modalities enabled by these platforms include antibody-drug conjugates (ADCs), CAR-T sdAbs, bispecific T-cell engagers (BiTEs), and V-Body-oligonucleotide conjugates. Valerio focuses on oncology, rare metabolic diseases, and immuno-inflammatory/autoimmune diseases.

Differentiator

Problem solved

Functional benefit

Products and services

• V-Body Platform A proprietary discovery and development platform based on ultra-small single-domain antibodies (~15 kDa) derived from fully synthetic human VH and humanized VHH libraries. Enables rapid identification and optimization of sdAbs with high affinity, specificity, enhanced tissue penetration, and intracellular delivery capabilities. Licensed to pharmaceutical and biotechnology partners for therapeutic development.
• Fully Integrated Chemistry Platform A state-of-the-art linker and payload chemistry platform enabling customized drug conjugation and optimized release at target sites. Provides end-to-end capabilities including antibody engineering and optimization, drug conjugate development, and preclinical and clinical development support.
• plaTON DNA Decoy Technology Platform Proprietary DNA Decoy Technology Platform developed for DNA repair exhaustion in cancer cells and abrogation of acquired resistance to targeted therapies including PARP inhibitors. Designed as a platform technology for oncology drug development.

Quantifiable outcome

• Development timeline of less than 2 months to generate highly effective and next-generation therapeutic candidates
• +1 more outcomes

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Nine partnerships are on record, tiered core and minor.

• Stealth-Mode Biotech CompanycoreStrategic or Co-development Partner · 18 May 2026Binding term-sheet signed for collaboration and exclusive worldwide license using V-Body platform to discover and generate novel targeted therapeutic compounds. Valerio leads research and discovery while partner assumes worldwide development, manufacturing, and commercialization. Potential aggregate milestone payments up to USD 200 million plus tiered royalties.
• InVimmunecoreStrategic or Co-development Partner · 4 May 2026Launch of InVimmune as a new company dedicated to developing differentiated in vivo cell therapy approaches with potential applications across oncology, fibrosis, autoimmune diseases, and additional indications. First indication in oncology. Valerio provides platform technology and scientific leadership through Olivier Demaria as CSO of both companies.
• Emglev TherapeuticscoreStrategic or Co-development Partner · 29 September 2024Acquisition of Emglev Therapeutics, a spin-off from Institut Curie, through Valerio's subsidiary Valour Bio. Deal involves share exchanges and aims to leverage Emglev's proprietary synthetic sdAb libraries and Valerio's expertise to advance development of single-domain antibody therapies for various diseases including cancer and autoimmune conditions.
• Institut CurieminorStrategic or Co-development PartnerEmglev Therapeutics, acquired by Valerio, was a spin-off from Institut Curie. Research collaboration and proximity to Institut Curie provides access to academic expertise and research capabilities.
• Frederick Ramsdell, PhD (Sonoma Biotherapeutics)minorOthers2025 Nobel Prize in Physiology or Medicine laureate and Chair of Scientific Advisory Board at Sonoma Biotherapeutics. Serves on InVimmune's Oncology Scientific Advisory Board.
• Alan Korman, PhD (BlueSphere Bio)minorOthersChief Scientific Officer and Board Member at BlueSphere Bio. Serves on InVimmune's Oncology Scientific Advisory Board.
• Matteo Iannacone, MD, PhD (San Raffaele Scientific Institute)minorOthersDirector of Division of Immunology, Transplantation and Infectious Diseases, Professor of Pathology, and Head of Dynamics of Immune Responses laboratory at San Raffaele Scientific Institute and University in Milan. Serves on InVimmune's Oncology Scientific Advisory Board.
• François RomagnéminorOthersFormer CSO of Innate Pharma and Professor of Immunotechnology. Serves on InVimmune's Oncology Scientific Advisory Board.
• Eric Vivier (Chair)coreOthersProfessor of Immunology at Aix-Marseille University and AP-HM, former Director of Centre d'Immunologie de Marseille-Luminy, co-founder of Innate Pharma. Chairs InVimmune's Oncology Scientific Advisory Board and serves as Observer to Valerio's Board of Directors.

Scale indicators10 records

Recent moves8 records

Expansion highlights5 records

Emerging players

• Compass Therapeutics: Clinical-stage oncology company developing antibody-based therapeutics including bispecifics and ADCs. Comparable as a small-cap antibody platform developer focused on oncology with similar partnership-oriented strategy, though more advanced in clinical development than Valerio.
• Orbital Therapeutics: Pre-clinical/early-stage RNA therapeutics company acquired by Bristol Myers Squibb for $1.5B in December 2025. Comparable as a recent precedent for a delivery-platform-focused biotech commanding a major pharma exit, and directly relevant because Valerio's incoming CEO (Gilles Besin) was Orbital's CSO. Provides a transaction benchmark for sdAb/RNA platform valuations.
• Wave Life Sciences: Clinical-stage company developing RNA-based therapeutics (PRISM platform for stereopure oligonucleotides) including oligonucleotide conjugates for extra-hepatic delivery. Comparable through Valerio's V-Body-Oligonucleotide Conjugate program targeting the same extra-hepatic RNA delivery opportunity, though Wave uses different chemistry and is further along clinically.
• Harbour BioMed: Clinical-stage biopharmaceutical company with a platform of heavy-chain-only antibodies (HCAb) and sdAb-based therapeutics. Comparable as a fellow sdAb-platform developer with multiple therapeutic programs, although Harbour BioMed is further along in clinical development and is a useful benchmark for sdAb platform value.

Broad incumbents

• Ablynx (Sanofi): The original sdAb platform company, founded on llama VHH technology and acquired by Sanofi for €3.9B in 2018. Highly relevant as the founding precedent that validated the sdAb therapeutic modality and is now Sanofi-owned — making it both a comparable and the most important incumbent competitor in the sdAb space.
• ImmunoGen (AbbVie): ADC pioneer (now part of AbbVie) that developed the foundational linker/payload chemistry used across the ADC field. Comparable as a broad incumbent that defines the competitive landscape Valerio's chemistry platform must compete in, though ImmunoGen is dramatically larger and more commercially mature.

Direct peers

• Bicycle Therapeutics: Clinical-stage company developing bicyclic peptide conjugates (Bicycles) as an alternative to antibodies for targeted therapeutic delivery. Highly comparable in approach — small-format targeting ligands, conjugate chemistry platform, oncology focus, and partnership-driven business model. Trades on Nasdaq and is a benchmark for small-format targeted therapeutic platforms.
• Innate Pharma: French-listed immuno-oncology company developing antibody-based therapeutics that engage innate immune cells (NK cells, T cells). Comparable given French listing, oncology focus, antibody platform approach, and the close personnel overlap with Valerio (CSO Olivier Demaria was at Innate; co-founder Eric Vivier is on Valerio's board).
• argenx: Commercial-stage leader in single-domain antibody (sdAb/VHH) therapeutics with multiple approved products (VYVGART and others). Most directly comparable company to Valerio, as both build pipelines around llama-derived VHH antibodies — argenx demonstrates the commercial validation and scale potential of the sdAb modality Valerio is pursuing.

Others

• Affinivax: Biotech acquired by GSK for $3.3B in 2022 for its Multiple Antigen Presenting System (MAPS) vaccine platform. Included as a relevant transaction benchmark because Valerio's incoming CEO (Gilles Besin) was VP and Head of Discovery at Affinivax. Provides a recent data point for platform-biotech exit valuations in comparable therapeutic modalities.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/valerio-tx

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Valerio Therapeutics